UK families seek justice as vaccine injury claims languish in bureaucratic limbo

Kam Miller wakes each morning still disbelieving that her husband is gone. Two years have passed since Neil died, and the shock remains audible in her voice when she speaks about it. "Every morning I wake up, and I still can't quite believe that he isn't here," she says. "Sometimes I even wonder if it was just a bad dream, then it hits me — this really happened."

On May 1, 2021, while Kam sat at their kitchen table in Leicester browsing for Neil's 51st birthday gifts, she heard a heavy thud from upstairs. She found him unconscious on the bathroom floor, making gurgling sounds. Her daughter Sophia began CPR while Kam called an ambulance, but it was too late. Neil, 50 years old, was pronounced dead at the scene. The cause was a rare reaction to the AstraZeneca COVID vaccine—a condition called vaccine-induced immune thrombocytopenia and thrombosis, or VITT, in which the immune system triggers dangerous blood clots. Neil had received his first dose enthusiastically on March 23, 2021. Within days, this fit man who played squash and football weekly developed a severe headache that sent him to the hospital. Scans revealed a clot near his heart, likely causing a minor heart attack. He never recovered.

Neil was the family's primary breadwinner, an IT manual writer. Now Kam works in customer services for a clothing company while supporting their two adult children—Sophia, 26, and Eshan, 22, who has struggled to begin pilot training due to grief. "On my income alone, I can't manage," Kam says. "We had a savings account, but I'm taking from it every month just to pay everything." She pays £50 for 50 minutes of grief counselling, a cost she can barely afford. "I'm terrified about my future," she adds. Kam filed a claim with the Vaccine Damage Payment Scheme in August 2022, more than a year after Neil's death. The scheme, established in 1979, is meant to provide reassurance that if something goes wrong with a government-recommended vaccine, the state will help. It pays a one-off, tax-free sum of £120,000 to those who have lost loved ones or those left "severely disabled"—defined as at least 60 percent disabled based on medical evidence.

But the scheme is failing under the weight of COVID-related claims. The NHS Business Services Authority, which runs it, received 4,178 claims concerning COVID-19 vaccines. Of these, 1,102 have been rejected, 56 didn't meet criteria for medical assessment, 1,727 are waiting for full medical records, and 1,230 are currently with independent medical assessors. Only 63 claimants have been notified they are entitled to payment. A Freedom of Information request revealed 144 unresolved claims submitted over 18 months ago. Kam's case, with a death certificate clearly stating heart attack caused by VITT, remains in limbo. "What more proof do they need?" she asks.

Kam is not alone. Gareth Eve's wife, radio presenter Lisa Shaw, died at 44 from AstraZeneca vaccine complications. Charlotte Wright's husband Stephen, a clinical psychologist, died at 32 from a stroke shortly after his January 2021 AstraZeneca jab. An inquest agreed the vaccine caused his death. Charlotte received £120,000 after a 16-month wait, but the payment barely covers a home for her and her two children. She gave up her job as a forest nursery teacher and now relies on food banks. "People should be made aware of how the families of those lost to vaccines continue to suffer," she says, emphasizing she is not anti-vaccine.

The 60 percent disability threshold excludes many others. Paul Scrivener, 51, a London Underground supervisor, developed Guillain-Barré syndrome—where the immune system attacks nerves—a month after his AstraZeneca vaccine. He spent a week in intensive care, unable to walk or breathe properly. Two years later, his breathing muscles remain so weak he cannot sleep on his back. His memory is affected, and nerve damage has impaired his sex life. The Vaccine Damage Payment Scheme assessors, who never physically examined him, determined his disabilities did not add up to 60 percent and denied him payment. Another patient spent over a year bedridden with nerve damage and muscle weakness, losing tens of thousands in wages, but was assessed at 40 percent disability and received nothing.

Professor Beverley Hunt, an NHS consultant haematologist who helped identify VITT, calls the scheme's criteria "a crude measure of how much someone has been affected." Many patients suffer neurological effects, fatigue, and difficulty with everyday life, making work impossible. Campaigners point to Scandinavian models as alternatives. In Norway, payments are calculated individually, uncapped, and require only proof of 15 percent disability. Many such schemes are funded partly by vaccine manufacturers rather than taxpayers. Sarah Moore, a lawyer representing 60 of 75 people taking legal action against AstraZeneca, argues that manufacturers profiting from vaccines should contribute to supporting those harmed. AstraZeneca declined to comment on ongoing litigation but stated that Vaxzevria has an "acceptable safety profile" and helped save over six million lives worldwide in its first year.

The broader context matters: COVID vaccines saved approximately 120,000 lives and prevented around 24 million cases across the UK. Over 151 million doses were administered. The adverse reactions, while tiny compared to lives saved, are not insignificant—hundreds of thousands of yellow card reports to the regulatory authority, with a small proportion involving serious events like blood clots and Guillain-Barré syndrome. Kam acknowledges this. "The family and I had Covid not long after Neil died. It was horrible, and I know the vaccines helped prevent deaths," she says. "But it makes me angry that Neil was doing what the Government asked of him to help keep society safe—so where are they now?" Her question hangs unanswered as the bureaucratic machinery grinds slowly on.